Related references
Note: Only part of the references are listed.Comparison of bypassing agents in patients on emicizumab using global hemostasis assays
Hande Kizilocak et al.
HAEMOPHILIA (2021)
Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
Sandra Le Quellec
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Emicizumab treatment and monitoring in a paediatric cohort: real-world data
Assaf A. Barg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort
Assaf A. Barg et al.
PEDIATRIC BLOOD & CANCER (2019)
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
Midori Shima et al.
HAEMOPHILIA (2019)
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study
Johannes Oldenburg et al.
HAEMOPHILIA (2019)
Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
Hande Kizilocak et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Emicizumab-kxwh: First Global Approval
Lesley J. Scott et al.
DRUGS (2018)
Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab
Yesim Dargaud et al.
HAEMATOLOGICA (2018)
In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents
R. Hartmann et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab
Yesim Dargaud et al.
HAEMATOLOGICA (2018)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
J. Mahlangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia Results from the Saudi national hemophilia screening program
Tarek Owaidah et al.
MEDICINE (2017)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Bispecific antibody mimicking factor VIII
Keiji Nogami
THROMBOSIS RESEARCH (2016)
Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test
Sophie Mathieu et al.
BLOOD COAGULATION & FIBRINOLYSIS (2015)
Factor VIII therapy for hemophilia A: current and future issues
Louis Aledort et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
Mechanisms and monitoring of bypassing agent therapy
M. Hoffman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery
Yesim Dargaud et al.
BLOOD (2010)
Treatment of hemophilia: a review of current advances and ongoing issues
Antonio Coppola et al.
JOURNAL OF BLOOD MEDICINE (2010)
New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors
Y. Dargaud et al.
HAEMOPHILIA (2008)
Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision
Y Dargaud et al.
HAEMOPHILIA (2005)
The measurement and application of thrombin generation
T Baglin
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Inhibitors in congenital coagulation disorders
NS Key
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Medical progress - The hemophilias - From royal genes to gene therapy
PM Mannucci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
